Part I. General Principles: 1. History Alois Gratwohl; 2. Pathophysiology of acute GVHD Carrie Kitko and James L. M. Ferrara; 3. Pathophysiology of chronic GVHD Kirk Schultz; 4. Animal models of chronic GVHD Yu-Wayne Chu, Ronald Gress, and Warren D. Shlomchik; 5. Incidence and trends Sally Arai, Mukta Arora, and Douglas Rizzo; 6. Clinical manifestations and natural history Mary Evelyn D. Flowers and Georgia Vogelsang; 7. Risk factors and predictive models Görgün Akpek and Stephanie J. Lee; 8. Biomarkers in prediction and monitoring Ernst Holler and Anne Dickinson; Part II. Clinical Management: 9. Diagnosis and staging Madan Jagasia, Howard M. Shulman, Alexandra H. Filipovich, and Steven Pavletic; 10. Chronic GVHD pharmacology and commonly used drugs T. Hughes and Timothy McGuire; 11. Prevention of chronic GVHD Andrea Bacigalupo and Nelson J. Chao; 12. Front line treatment of chronic GVHD Paul J. Martin and Andrew L. Gilman; 13. Salvage treatment of chronic GVHD Hildegard T. Greinix and Joseph H. Antin; 14. Response measurement David Jacobsohn, Sandra A. Mitchell, and Steven Z. Pavletic; 15. General principles in ancillary and supportive care Paul A. Carpenter and Dan R. Couriel; Part III. Organ Site or System Specific Manifestations: 16. Skin Edward W. Cowen and Sharon R. Hynes; 17. Mouth Nathaniel S. Treister, Mark M. Schubert, and Jane M. Fall-Dickson; 18. Eyes Stella K. Kim, Janine A. Smith, and James P. Dunn Jr.; 19. Genitalia Maria L. Turner and Pamela Stratton; 20. Gastrointestinal (including nutritional support) Miwa Sakai and George B. McDonald; 21. Pulmonary Javier Bolaños-Meade and Jason W. Chien; 22. Hematologic Corey Cutler; 23. Neurologic Harry Openshaw; 24. Musculoskeletal Li Li, Leighton Chan, and Lynn H. Gerber; 25. Infections Juan Gea-Banacloche and Michael Boeckh; 26. Metabolic and endocrine effects Paul A. Carpenter and Jean E. Sanders; 27. Other manifestations Kristin Baird and Andrew L. Gilman; 28. Psycho-social issues Loretta Williams and Karen L. Syrjala; 29. Secondary and late effects Gérard Socié and H. J. Deeg; 30. Quality of life assessments Sandra A. Mitchell and Bryce B. Reeve; Part IV. Special Considerations in Chronic GVHD: 31. Clinical trials design Paul J. Martin, Donna Przepiorka, and Stephanie J. Lee; 32. Unique clinical situations Mohamad Mohty, Juliet N. Barker, and Claudio Anasetti; 33. Pediatric chronic GVHD Kristin Baird, Alan S. Wayne, and David A. Jacobsohn; 34. Coordination and continuity of interdisciplinary practice Viki Anders, Carina Moravec, and Sandra A. Mitchell; 35. Patient and family education, advocacy, and support groups Kathleen M. Castro, Susan Stuart, Myra J. Jacobs, and Paula Kim; 36. Future directions Stephanie J. Lee.
